With Allergan's rival on the regulatory ropes, AbbVie posts more promising late-stage data for elagolix
AbbVie picked a good day to unveil another positive set of late-stage data from their uterine fibroid program for elagolix, now on the market as Orilissa for a different indication.
Just hours after Allergan revealed that their application for a rival therapy had been hit with a rejection letter from the FDA, the AbbVie team says their Phase III ELARIS UF-EXTEND extension study of elagolix hit a clinical response rate of 88%. That comes on top of two clearly upbeat Phase III readouts showing a high rate of responses, defined by a significant drop in menstrual blood loss.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.